Effects of Tolvaptan, an Oral Vasopressin V2 Receptor Antagonist, in Hyponatremia

American Journal of Kidney Diseases

Volumn 50, Issue 2, 2007, Pages 184-187

  Madias, Nicolaos E ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; PLACEBO; SATAVAPTAN; SODIUM; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HUMAN; HYPONATREMIA; SODIUM BLOOD LEVEL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; BENZAZEPINES; HUMANS; HYPONATREMIA; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, VASOPRESSIN;

EID: 34447649720     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.06.011     Document Type: Editorial

References (13)

1. Upadhyay A., Jaber B.L., and Madias N.E. Incidence and prevalence of hyponatremia. Am J Med 119 suppl 1 (2006) S30-S35
2. Renneboog B., Musch W., Vandemergel X., Manto M.U., and Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119 (2006) 71.e1-71.e8
3. Adrogué H.J., and Madias N.E. Hyponatremia. N Engl J Med 342 (2000) 1581-1589
4. Schrier R.W., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355 (2006) 2099-2112
5. Astellas Pharma US, Inc: Vaprisol (conivaptan hydrochloride injection) product monograph. Deerfield, IL, 2006
6. Greenberg A., and Verbalis J.G. Vasopressin receptor antagonists. Kidney Int 69 (2006) 2124-2130
7. Palm C., Pistrosch F., Herbrig K., and Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 119 suppl 1 (2006) S87-S92
8. Gerbes A.L., Gülberg V., Ginès P., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology 124 (2003) 933-939
9. Soupart A., Gross P., Legros J.-J., et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1 (2006) 1154-1160
10. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials. JAMA 297 (2007) 1332-1343
11. Feldman B.J., Rosenthal S.M., Vargas G.A., et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352 (2005) 1884-1890
12. Decaux G., Vandergheynst F., Bouko Y., Parma J., Vassart G., and Vilain C. Nephrogenic syndrome of inappropriate antidiuresis in adults: High phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 18 (2007) 606-612
13. Soupart A., Silver S., Schroeder B., Sterns R., and Decaux G. Comparison of mortality and brain composition in hyponatremic rats treated with vasopressin V1-V2 receptor antagonists or water diuresis. J Am Soc Nephol 14 (2003) A747 (abstr)